Published November 14, 2022
| Version 1
Report
Open
Genetic assessment of all SLC family members
Authors/Creators
- 1. Pfizer
- 2. Bayer
- 3. CeMM
Description
The genetic assessment is performed both variant and gene based for all SLC family members
Notes
REsolution has received funding from the Innovative Medicines Initiative 2 Joint Undertaking under grant agreement No 101034439. This Joint Undertaking receives support from the European Union's Horizon 2020 research and innovation programme and EFPIA. This article reflects only the authors' views and neither IMI nor the European Union and EFPIA are responsible for any use that may be made of the information contained therein.
Files
IMI2_REsolution_D1_6.pdf
Files
(277.8 kB)
| Name | Size | Download all |
|---|---|---|
|
md5:6c061d6901d47a5ba655e48b47f7ec6b
|
277.8 kB | Preview Download |